Abdallah, Chadi G. http://orcid.org/0000-0001-5783-6181
De Feyter, Henk M.
Averill, Lynnette A.
Jiang, Lihong
Averill, Christopher L. http://orcid.org/0000-0001-7575-6142
Chowdhury, Golam M. I.
Purohit, Prerana
de Graaf, Robin A.
Esterlis, Irina
Juchem, Christoph
Pittman, Brian P.
Krystal, John H.
Rothman, Douglas L.
Sanacora, Gerard
Mason, Graeme F.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH101498)
Article History
Received: 17 February 2018
Revised: 18 June 2018
Accepted: 19 June 2018
First Online: 28 June 2018
Competing interests
: CGA has served as a consultant and/or on advisory boards for Genentech and Janssen, and editor of “Chronic Stress” for Sage Publications, Inc. JHK is a consultant for AbbVie, Inc., Amgen, Astellas Pharma Global Development, Inc., AstraZeneca Pharmaceuticals, Biomedisyn Corporation, Bristol–Myers Squibb, Eli Lilly and Company, Euthymics Bioscience, Inc., Neurovance, Inc., FORUM Pharmaceuticals, Janssen Research & Development, Lundbeck Research USA, Novartis Pharma AG, Otsuka America Pharmaceutical, Inc., Sage Therapeutics, Inc., Sunovion Pharmaceuticals, Inc., and Takeda Industries. JHK is on the Scientific Advisory Board for Lohocla Research Corporation, Mnemosyne Pharmaceuticals, Inc., Naurex, Inc., and Pfizer. JHK is a stockholder in Biohaven Pharmaceuticals, holds stock options in Mnemosyne Pharmaceuticals, Inc., holds patents for Dopamine and Noradrenergic Reuptake Inhibitors in Treatment of Schizophrenia, U.S. Patent No. 5,447,948 (issued September 5, 1995), and Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014); and filed a patent for Intranasal Administration of Ketamine to Treat Depression. U.S. Application No. 14/197,767 (filed on March 5, 2014); U.S. application or Patent Cooperation Treaty international application No. 14/306,382 (filed on June 17, 2014). GS reports personal consulting fees from Alkermes, Allergan, Biohaven Pharmaceuticals, Eli Lilly and Co., Genentech, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lundbeck Research USA, Merck & Co., Naurex, Navitor Pharmaceuticals, Noven Pharmaceuticals, Teva Pharmaceuticals Industries, Taisho Pharmaceutical Co., Takeda Pharmaceutical Co., Sage Pharmaceuticals, Inc., Sevier, Valeant Pharmaceuticals, and Vistagen Therapeutics, Inc. GS has grants and research contracts from Eli Lilly and Co., Janssen Pharmaceuticals, Merck & Co., and Sevier; and support from Sanofi-Aventis, in the form of free medication for an NIH sponsored study over the last 36 months. In addition, Dr. GS is a stockholder and holds stock options in Biohaven Pharmaceuticals; and has a patent for Glutamate Modulating Agents in the Treatment of Mental Disorders, U.S. Patent No. 8,778,979 (issued July 15, 2014) with royalties paid from Biohaven Pharmaceuticals. GFM is a consultant for Sumitomo Dainippon Pharma Co. Ltd. and UCB Pharma SA, and serves on the Scientific Advisory Board of Elucidata, Inc. All other authors report no competing interests.
: All study procedures were approved by an institutional review board (ClinicalTrials.gov NCT02037035).